Home / Stocks / Yatharth Hosp & Tra C S L
YATHARTH

Yatharth Hosp & Tra C S L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,078.5

Change

-12.6 (-1.15%)

Open

₹1,089.7

Prev. Close

₹1,091.1

Day High

₹1,101.75

Day Low

₹1,071.75

Volume Analysis

Traded

140,306

Delivered

50,954

Delivery %

36.32%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (23.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (3)

  • •Strong 3-year EPS growth (21.9%)
  • •Strong 3-year revenue growth (36.2%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,126.25 ₹1,114.0 ₹1,096.25 ₹1,084.0 ₹1,066.25 ₹1,054.0 ₹1,036.25
Fibonacci ₹1,114.0 ₹1,102.54 ₹1,095.46 ₹1,084.0 ₹1,072.54 ₹1,065.46 ₹1,054.0
Camarilla ₹1,086.75 ₹1,084.0 ₹1,081.25 ₹1,084.0 ₹1,075.75 ₹1,073.0 ₹1,070.25

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+59.73%

1 Week

+1.71%

1 Month

+16.96%

3 Months

+26.12%

6 Months

+25.09%

1 Year

+39.78%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹282.58

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

7.95%

Net margin 12.25% × asset turnover 0.47x × equity multiplier 1.38x

Company Overview

Sector

Healthcare

Market Cap

₹10,222 Cr

P/E (TTM)

53.6

ROE

10.2%

Book Value

₹195.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Yatharth Hosp & Tra C S L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 68/100. The strongest factor is Financial Strength (100/100), while Valuation (16/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (23.0%); promoter holding is falling. Strong 3-year EPS growth (21.9%).

TopFund Score — Fundamentals Quality

68/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

100

Valuation

16

Cash Flow

65

Corporate Governance

43

Momentum

81

Institutional Ownership

63

Business Quality

69

Risk & Volatility

65

Liquidity

54

From Screener.in

  • +Company is expected to give good quarter
  • +Company has delivered good profit growth of 57.1% CAGR over last 5 years
  • +Company's working capital requirements have reduced from 101 days to 80.1 days
  • −Company has a low return on equity of 12.1% over last 3 years.
  • −Company might be capitalizing the interest cost
  • −Promoter holding has decreased over last 3 years: -10.5%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

CCI approved Yatharth Hospital's ₹31,500 million preferential issue to Rasmalai Limited for 24.87% stake.

CARE report for Q2FY27 shows nil deviation, ₹48.45 crore unutilised, extension till March 31, 2027.

Audio recording of Q2FY27 earnings call held on November 4, 2026 is now available online.

We hereby submit Newspaper Publication of Unaudited Financial Results - Q2FY27.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 171 167 178 212 218 219 232 258 279 320 342 393 431
Expenses + 126 120 131 158 163 164 175 193 215 246 262 301 329
Operating Profit 46 46 47 54 55 55 57 64 65 74 80 92 102
OPM % 27.0% 28.0% 26.0% 25.0% 25.0% 25.0% 25.0% 25.0% 23.0% 23.0% 23.0% 23.0% 24.0%
Other Income + 4 5 6 4 3 4 5 9 9 8 7 4 5
Interest 3 0 0 3 2 2 1 0 0 1 5 7 8
Depreciation 7 8 8 11 16 17 13 15 19 24 30 28 33
Profit before tax 40 44 44 43 40 40 49 59 55 57 52 61 66
Tax % 30.0% 33.0% 13.0% 29.0% 23.0% 24.0% 20.0% 28.0% 25.0% 25.0% 14.0% 26.0% 26.0%
Net Profit + 28 29 38 30 31 30 39 42 41 43 45 45 48
EPS in Rs 3 3 4 4 4 3 4 4 4 5 5 5 5
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 34 21 24 37 27 31 30 22 28 46 47 52 54

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 71 78 91 136 215 375 478 635 886 1,207 1,486
Expenses + 53 60 71 98 147 263 343 453 655 902 1,138
Operating Profit 18 18 20 38 68 112 135 182 230 305 348
OPM % 25.0% 24.0% 22.0% 28.0% 32.0% 30.0% 28.0% 29.0% 26.0% 25.0% 23.0%
Other Income + 0 0 0 0 1 2 3 16 11 25 24
Interest 6 5 7 20 20 23 23 11 12 19 21
Depreciation 7 6 8 21 21 28 28 29 57 88 115
Profit before tax 5 8 5 -2 28 63 88 157 172 224 236
Tax % 41.0% 23.0% 21.0% -18.0% 30.0% 30.0% 25.0% 27.0% 24.0% 24.0% —
Net Profit + 3 6 4 -2 20 44 66 114 131 170 182
EPS in Rs 1 1 1 0 3 7 10 13 14 18 20
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — 10 17 49 58 74 27 33 40 36 50

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 29 41 39 38 56 51 117 788 1,509 1,684 1,779
Borrowings + 85 125 175 194 193 264 267 85 12 264 468
Other Liabilities + 10 11 26 39 43 45 36 60 114 218 247
Total Liabilities 138 193 257 287 309 426 486 1,019 1,731 2,262 2,591
Fixed Assets + 54 53 164 189 251 303 299 442 605 1,250 1,322
CWIP 64 110 65 62 0 0 0 0 222 102 242
Investments 0 0 0 0 0 0 0 0 74 2 2
Other Assets + 20 30 27 36 58 123 187 577 829 909 1,025
Total Assets 138 193 257 287 309 426 486 1,019 1,731 2,262 2,591
Equity Capital 14 16 16 16 16 66 66 86 96 96 96

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 25 17 17 39 44 60 64 -3 131 205
Cash from Investing Activity + -50 -51 -78 -43 -21 -52 -20 -226 -388 -598
Cash from Financing Activity + 26 43 47 5 -19 -1 -18 304 509 254
Net Cash Flow 1 9 -13 1 3 7 26 75 253 -140
Free Cash Flow 24 16 -60 -4 24 21 44 -96 -171 -112
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 148 103 99 109 67 65 75 22 68 94

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 66.44% → 55.8%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 22.15% 20.15% 19.16% 20.2% 17.27% 20.35% 20.5% 23.16% 27.01% 26.94% 27.74% 26.21%
Promoters 66.44% 66.54% 66.54% 66.54% 61.44% 61.64% 61.64% 61.64% 55.8% 55.8% 55.8% 55.8%
FII 2.59% 3.99% 4.9% 6.28% 9.78% 4.45% 4.34% 6.51% 6.18% 5.25% 5.62% 7.05%
DII 8.81% 9.3% 9.4% 6.97% 11.5% 13.56% 13.52% 8.71% 11.02% 12.0% 10.84% 10.94%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Yatharth Hosp & Tra C S L (this stock) 10,222 53.6 5.44 10.2%
Symbiotec Pharmalab Ltd 10,354 70.0 7.6 11.7%
Blue Jet Healthcare Ltd 9,989 70.9 — 52.1%
Jupiter Life Line Hosp L 9,507 50.0 5.84 13.1%
Park Medi World Limited 11,039 43.1 5.12 16.8%
Strides Pharma Sci Ltd 9,353 16.2 2.74 20.0%
Paras Healthcare Limited 9,284 129.0 — 13.0%

Which Mutual Funds Hold Yatharth Hosp & Tra C S L?

Frequently Asked Questions about Yatharth Hosp & Tra C S L

Community Sentiment

What are other investors saying about Yatharth Hosp & Tra C S L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.